Fangsheng Pharmaceutical(SH:603998) Ge Long Hui·2025-12-08 08:53Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has successfully negotiated to include its proprietary product, Yao Xue Qu Feng Zhi Tong Granules, in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, which is expected to positively impact the product's market promotion and sales scale [1] Group 1 - The product Yao Xue Qu Feng Zhi Tong Granules is an innovative traditional Chinese medicine developed by the company [1] - The inclusion in the 2025 Medical Insurance Catalog will enhance the product's market access and sales potential [1] - The company anticipates a positive impact on future operating performance and market share, although no significant short-term effects on operating results are expected [1]